Serono has oral MS pill Mylinax, which it hopes to file for approval in 2008: "Serono's most important product is Rebif, an injectable drug for MS. Its long-term future is in doubt, however, as scientists work to develop more convenient oral treatments.Serono has its own oral MS pill Mylinax, which it hopes to file for approval in 2008, while Glaxo has a less-advanced rival, dubbed '699, that is currently stalled in Phase II clinical development.Merging the two companies would therefore give Glaxo two 'shots on goal' in a potentially lucrative new business area....Glaxo executives are already familiar with some of Serono's operations, since Glaxo Wellcome sold its research centre in Geneva to the Swiss group in 1997.On the downside, analysts noted that Serono currently has a U.S. marketing arrangement for Rebif with Glaxo's arch-rival Pfizer Inc. , which may have to be unwound."